TrialCurveCLL12: reconstructed Kaplan–Meier curves
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Hemasphere. 2026 Jun 15;10(6):e70385. doi: 10.1002/hem3.70385 |
|---|---|
| DOI | 10.1002/hem3.70385 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Event-free survival (EFS) — CLL12 trial, patients from all trial arms
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Non-IGLV3-21 not reached; IGLV3-21G110 47.8 months; IGLV3-21R110 44.6 months. Survival at 18 months: Non-IGLV3-21 93%; IGLV3-21G110 100%; IGLV3-21R110 68%. Hazard ratio Non-IGLV3-21 vs IGLV3-21R110 0.29 (95% CI 0.17–0.48).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Non-IGLV3-21 | 481 | 144 | not reached |
| IGLV3-21G110 | 9 | 5 | 47.8 |
| IGLV3-21R110 | 25 | 17 | 44.6 |
- Non-IGLV3-21 vs IGLV3-21R110: reconstructed HR 0.29 (95% CI 0.17–0.48)
- IGLV3-21G110 vs IGLV3-21R110: reconstructed HR 0.65 (95% CI 0.24–1.77)
Landmark survival (reconstructed)
| Time | Non-IGLV3-21 | IGLV3-21G110 | IGLV3-21R110 |
|---|---|---|---|
| 6 mo | 98.7% | 100.0% | 96.0% |
| 12 mo | 95.7% | 100.0% | 72.0% |
| 18 mo | 92.6% | 100.0% | 68.0% |
| 24 mo | 88.1% | 88.9% | 55.3% |
| 36 mo | 80.9% | 66.7% | 51.0% |
| 48 mo | 75.9% | 50.0% | 45.9% |
| 60 mo | 71.3% | 33.3% | 30.6% |
Event-free survival (EFS) — CLL12 trial, placebo and ibrutinib arms
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Placebo, IGLV3-21R110 21.9 months; Placebo, no IGLV3-21R110 54.9 months; Ibrutinib, IGLV3-21R110 60.2 months; Ibrutinib, no IGLV3-21R110 not reached. Survival at 18 months: Placebo, IGLV3-21R110 58%; Placebo, no IGLV3-21R110 84%; Ibrutinib, IGLV3-21R110 90%; Ibrutinib, no IGLV3-21R110 94%. Hazard ratio Placebo, no IGLV3-21R110 vs Placebo, IGLV3-21R110 0.45 (95% CI 0.22–0.89).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Placebo, IGLV3-21R110 | 12 | 9 | 21.9 |
| Placebo, no IGLV3-21R110 | 169 | 85 | 54.9 |
| Ibrutinib, IGLV3-21R110 | 10 | 5 | 60.2 |
| Ibrutinib, no IGLV3-21R110 | 172 | 34 | not reached |
- Placebo, no IGLV3-21R110 vs Placebo, IGLV3-21R110: reconstructed HR 0.45 (95% CI 0.22–0.89)
- Ibrutinib, IGLV3-21R110 vs Placebo, IGLV3-21R110: reconstructed HR 0.45 (95% CI 0.15–1.36)
- Ibrutinib, no IGLV3-21R110 vs Placebo, IGLV3-21R110: reconstructed HR 0.14 (95% CI 0.07–0.30)
Landmark survival (reconstructed)
| Time | Placebo, IGLV3-21R110 | Placebo, no IGLV3-21R110 | Ibrutinib, IGLV3-21R110 | Ibrutinib, no IGLV3-21R110 |
|---|---|---|---|---|
| 6 mo | 91.7% | 97.6% | 100.0% | 98.8% |
| 12 mo | 58.3% | 91.3% | 90.0% | 97.0% |
| 18 mo | 58.3% | 84.4% | 90.0% | 94.4% |
| 24 mo | 41.7% | 76.0% | 78.8% | 91.8% |
| 36 mo | 41.7% | 63.1% | 67.5% | 89.1% |
| 48 mo | 31.2% | 54.3% | 67.5% | 85.3% |
| 60 mo | 20.8% | 49.9% | 54.0% | 78.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.31, reconstructed 0.304 pass
- hazard ratio (direction inferred): printed 0.44, reconstructed 0.452 pass
- hazard ratio: printed 2.31, reconstructed 2.24 pass
- hazard ratio: printed 2.99, reconstructed 2.96 pass
Overall survival (OS) — CLL12 trial, placebo and ibrutinib arms
From figure panel D · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Placebo, IGLV3-21R110 not reached; Placebo, no IGLV3-21R110 not reached; Ibrutinib, IGLV3-21R110 not reached; Ibrutinib, no IGLV3-21R110 not reached. Survival at 18 months: Placebo, IGLV3-21R110 100%; Placebo, no IGLV3-21R110 100%; Ibrutinib, IGLV3-21R110 100%; Ibrutinib, no IGLV3-21R110 98%. Hazard ratio Placebo, no IGLV3-21R110 vs Ibrutinib, IGLV3-21R110 0.89 (95% CI 0.12–6.81).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Placebo, IGLV3-21R110 | 12 | — | not reached |
| Placebo, no IGLV3-21R110 | 169 | 14 | not reached |
| Ibrutinib, IGLV3-21R110 | 10 | 1 | not reached |
| Ibrutinib, no IGLV3-21R110 | 172 | 11 | not reached |
- Placebo, no IGLV3-21R110 vs Ibrutinib, IGLV3-21R110: reconstructed HR 0.89 (95% CI 0.12–6.81)
- Ibrutinib, no IGLV3-21R110 vs Ibrutinib, IGLV3-21R110: reconstructed HR 0.66 (95% CI 0.09–5.16)
Landmark survival (reconstructed)
| Time | Placebo, IGLV3-21R110 | Placebo, no IGLV3-21R110 | Ibrutinib, IGLV3-21R110 | Ibrutinib, no IGLV3-21R110 |
|---|---|---|---|---|
| 6 mo | 100.0% | 100.0% | 100.0% | 100.0% |
| 12 mo | 100.0% | 100.0% | 100.0% | 98.8% |
| 18 mo | 100.0% | 100.0% | 100.0% | 98.1% |
| 24 mo | 100.0% | 100.0% | 100.0% | 97.5% |
| 36 mo | 100.0% | 98.7% | 100.0% | 96.8% |
| 48 mo | 100.0% | 95.7% | 100.0% | 94.5% |
| 60 mo | 100.0% | 94.0% | 87.5% | 94.5% |
Checks against the published figure
- hazard ratio: printed 1.46, reconstructed 1.51 pass
- hazard ratio (direction inferred): printed 0.77, reconstructed 0.761 pass
Overall survival (OS) — CLL12, all trial arms, by IGHV mutational status and IGLV3-21R110 expression
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Mutated IGHV & no IGLV3-21R110 (n=344) not reached; Mutated IGHV & IGLV3-21R110 (n=18) not reached; Unmutated IGHV & no IGLV3-21R110 (n=143) not reached; Unmutated IGHV & IGLV3-21R110 (n=5) not reached. Survival at 18 months: Mutated IGHV & no IGLV3-21R110 (n=344) 99%; Mutated IGHV & IGLV3-21R110 (n=18) 94%; Unmutated IGHV & no IGLV3-21R110 (n=143) 99%; Unmutated IGHV & IGLV3-21R110 (n=5) 100%. Hazard ratio Mutated IGHV & no IGLV3-21R110 (n=344) vs Unmutated IGHV & IGLV3-21R110 (n=5) 0.26 (95% CI 0.03–1.94).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Mutated IGHV & no IGLV3-21R110 (n=344) | 344 | 19 | not reached |
| Mutated IGHV & IGLV3-21R110 (n=18) | 18 | 1 | not reached |
| Unmutated IGHV & no IGLV3-21R110 (n=143) | 143 | 11 | not reached |
| Unmutated IGHV & IGLV3-21R110 (n=5) | 5 | 1 | not reached |
- Mutated IGHV & no IGLV3-21R110 (n=344) vs Unmutated IGHV & IGLV3-21R110 (n=5): reconstructed HR 0.26 (95% CI 0.03–1.94)
- Mutated IGHV & IGLV3-21R110 (n=18) vs Unmutated IGHV & IGLV3-21R110 (n=5): reconstructed HR 0.25 (95% CI 0.02–4.06)
- Unmutated IGHV & no IGLV3-21R110 (n=143) vs Unmutated IGHV & IGLV3-21R110 (n=5): reconstructed HR 0.28 (95% CI 0.04–2.22)
Landmark survival (reconstructed)
| Time | Mutated IGHV & no IGLV3-21R110 (n=344) | Mutated IGHV & IGLV3-21R110 (n=18) | Unmutated IGHV & no IGLV3-21R110 (n=143) | Unmutated IGHV & IGLV3-21R110 (n=5) |
|---|---|---|---|---|
| 6 mo | 100.0% | 100.0% | 100.0% | 100.0% |
| 12 mo | 99.7% | 100.0% | 99.3% | 100.0% |
| 18 mo | 99.4% | 94.4% | 99.3% | 100.0% |
| 24 mo | 99.4% | 94.4% | 98.5% | 100.0% |
| 36 mo | 98.1% | 94.4% | 97.8% | 100.0% |
| 48 mo | 96.6% | 94.4% | 94.5% | 100.0% |
| 60 mo | 95.8% | 94.4% | 93.6% | 66.7% |
Checks against the published figure
- hazard ratio: printed 3.72, reconstructed 3.52 pass
- hazard ratio: printed 0.95, reconstructed 0.974 pass
Overall survival (OS) — CLL12 ibrutinib arm, by IGHV mutational status and IGLV3-21R110 expression
From figure panel D · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Unmutated IGHV & IGLV3-21R110 (n=3) 58.1 months; Unmutated IGHV & no IGLV3-21R110 (n=67) not reached; Mutated IGHV & IGLV3-21R110 (n=7) not reached; Mutated IGHV & no IGLV3-21R110 (n=102) not reached. Survival at 18 months: Unmutated IGHV & IGLV3-21R110 (n=3) 100%; Unmutated IGHV & no IGLV3-21R110 (n=67) 98%; Mutated IGHV & IGLV3-21R110 (n=7) 100%; Mutated IGHV & no IGLV3-21R110 (n=102) 98%. Hazard ratio Unmutated IGHV & no IGLV3-21R110 (n=67) vs Unmutated IGHV & IGLV3-21R110 (n=3) 0.15 (95% CI 0.02–1.34).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Unmutated IGHV & IGLV3-21R110 (n=3) | 3 | 1 | 58.1 |
| Unmutated IGHV & no IGLV3-21R110 (n=67) | 67 | 4 | not reached |
| Mutated IGHV & IGLV3-21R110 (n=7) | 7 | — | not reached |
| Mutated IGHV & no IGLV3-21R110 (n=102) | 102 | 7 | not reached |
- Unmutated IGHV & no IGLV3-21R110 (n=67) vs Unmutated IGHV & IGLV3-21R110 (n=3): reconstructed HR 0.15 (95% CI 0.02–1.34)
- Mutated IGHV & no IGLV3-21R110 (n=102) vs Unmutated IGHV & IGLV3-21R110 (n=3): reconstructed HR 0.18 (95% CI 0.02–1.48)
Landmark survival (reconstructed)
| Time | Unmutated IGHV & IGLV3-21R110 (n=3) | Unmutated IGHV & no IGLV3-21R110 (n=67) | Mutated IGHV & IGLV3-21R110 (n=7) | Mutated IGHV & no IGLV3-21R110 (n=102) |
|---|---|---|---|---|
| 6 mo | 100.0% | 100.0% | 100.0% | 100.0% |
| 12 mo | 100.0% | 98.4% | 100.0% | 98.9% |
| 18 mo | 100.0% | 98.4% | 100.0% | 97.8% |
| 24 mo | 100.0% | 96.8% | 100.0% | 97.8% |
| 36 mo | 100.0% | 96.8% | 100.0% | 95.5% |
| 48 mo | 100.0% | 95.1% | 100.0% | 92.7% |
| 60 mo | 50.0% | 95.1% | 100.0% | 92.7% |
Checks against the published figure
- hazard ratio: printed 7.2, reconstructed 6.74 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- CEPHEUS: Overall survival; Progression-free survival
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials